|Bid||89.61 x 100|
|Ask||89.88 x 200|
|Day's Range||89.28 - 91.00|
|52 Week Range||86.55 - 147.17|
|PE Ratio (TTM)||24.62|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||118.72|
Matthew Cheslock joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest moves in the markets.
Whether you're a liberal fan of MSNBC or a conservative viewer of Fox, there is no escaping ads for psoriasis treatments.
Celgene could go private in 2019 to avoid volatility as key cancer drug Revlimid begins to lose patent protection in the mid-2020s, an analyst suggested Wednesday.
Celgene (CELG) hasn't had a great year, with the shares falling 12% since the start of 2018, on top of a lackluster performance last year. But things aren’t as bad as they may seem, argues RBC Capital ...
The biotech's CFO talks about the future for ozanimod, challenges to Revlimid, and more at the Barclays healthcare conference.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, tumbled alongside the broader market in February. In fact, IBB’s February loss surpassed those ...
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / U.S. markets hiked higher on Friday, with the Dow Jones breaking above the 25,000 threshold, on the back of a stronger-than-expected jobs report. The Dow Jones ...
Healthcare sector has proven itself to be one of the most resilient sectors of the US economy. Since healthcare cannot be outsourced and represents an expense that people usually cut on last during economic downturns, investing in healthcare stocks is a good way to recession-proof your portfolio. Moreover, the sector itself is comprised of many […]
Biotech is a lot like venture capital. Trendlines also show investment is on the rise. In an effort to measure the size, scope and growth trajectory of this startup funding space, Crunchbase News assembled a few data sets of the largest corporate venture investors in biotech.
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Over the last one-month, outflows of investor capital in ETFs holding CELG totaled $17.10 billion.